Evidence map›Paper›PMID 41080735›Full record

ArticleMaterials today. Bio2025

Cholesterol surface-modified oncolytic adenovirus enriched with apolipoprotein E penetrates the blood-brain barrier to target glioblastoma immunotherapy.

Aodi Niu, Yuqing Lv, Yuxuan Chen, Yuxuan Liu, Chengjian Luo, Mengqing Zheng, Yeyu Shen, Junjia He, Dongni Yao, Huanrong Lan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026
    Review
  2. Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aodi NiuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
Yuqing LvCenter for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.
Yuxuan ChenCenter for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.
Yuxuan LiuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
Chengjian LuoSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
Mengqing ZhengSchool of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
Yeyu ShenCenter for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.
Junjia HeCenter for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.
Dongni YaoCenter for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.
Huanrong LanDepartment of Surgical Oncology, Hangzhou Cancer Hospital, Hangzhou, 310002, China.
Hai ZouDepartment of Emergency and Critical Care Medicine, Pudong New Area People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 201299, China.
Tong GeEmergency Department, Tiantai People's Hospital of Zhejiang Province (Tiantai Branch of Zhejiang Provincial People's Hospital), Hangzhou Medical College, Taizhou, 317200, China.
Xiaozhou MouCenter for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) remains a therapeutic challenge due to its aggressive behaviour and the limitation of drug delivery by the blood-brain barrier (BBB). Conventional oncolytic adenoviruses (OAs) suffer from poor targeting efficiency. To overcome this limitation, we developed a cholesterol-modified OA (OA@Cho). This engineered virus actively regulates protein corona formation in the bloodstream, selectively enriching apolipoprotein E (ApoE). By exploiting low-density lipoprotein receptor (LDLR)-mediated BBB transcytosis, OA@Cho achieves precise glioma targeting and enhances therapeutic delivery. Critically, upon reaching the GBM site, OA@Cho induces an anti-tumor immune response, turning "cold" tumors into "hot" tumors by inducing immunogenic cell death (ICD). The proposed "surface modification-ApoE enrichment-receptor-mediated" paradigm establishes a transformative platform that enables oncolytic viruses to bypass biological barriers, thereby advancing targeted viral therapies against CNS malignancies with high translational relevance.

Indexed as

Apolipoprotein EBlood-brain barrierCholesterolImmunogenic cell deathOncolytic adenovirus

Identifiers

PMID41080735
PMCPMC12509134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.